Study identifier:NIS-CRU-XXX-2014/1
ClinicalTrials.gov identifier:NCT02230241
EudraCT identifier:N/A
CTIS identifier:N/A
CEntralized Pan-Russian survey of tHE Undertreatment of hypercholeSterolemia II
dyslipidaemia
N/A
No
-
All
2700
Observational
N/A
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 May 2016 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Cohort 1 Subjects of either gender and any race, aged ≥ 18 years, at moderate to very high CV risk, on lipid-lowering pharmacotherapy for at least 3 months (90 days), with no dose change for a minimum of 8 weeks (56 days). Before starting any study-related activities, the investigator should obtain written informed consent personally signed and dated by the subject. | - |